Blog

The immunotherapy success rate for breast cancer has become an increasingly important question as immune-based treatments continue to reshape oncology. While chemotherapy, hormone therapy, and targeted therapies have long been standard approaches, immunotherapy has emerged as a transformative option, particularly for aggressive types like triple-negative breast cancer (TNBC). Patients and clinicians alike now ask: How effective is immunotherapy for breast cancer, and who benefits the most?

Read More About Triple-Negative Breast Cancer on OncoDaily

Understanding Immunotherapy in Breast Cancer

To evaluate the immunotherapy success rate for breast cancer, it’s essential to understand how these treatments work. Immunotherapy activates the body’s immune system to detect and destroy tumor cells. However, breast cancer cells often evade immune detection by exploiting inhibitory pathways such as PD-1 and PD-L1, which suppress immune responses. Drugs that block these pathways, known as checkpoint inhibitors, restore immune activity and enable the body to attack cancer cells.

Among the breast cancer subtypes, TNBC is considered the most responsive to immunotherapy because it tends to have higher levels of tumor-infiltrating lymphocytes and PD-L1 expression. These immune characteristics make TNBC more immunogenic compared to hormone receptor–positive (HR+) or HER2-positive tumors.

FDA-Approved Immunotherapy Treatments

The most notable breakthroughs defining the immunotherapy success rate for breast cancer come from trials involving atezolizumab and pembrolizumab. Atezolizumab (Tecentriq) was the first immune checkpoint inhibitor approved for breast cancer. In the landmark IMpassion130 trial, atezolizumab combined with nab-paclitaxel extended progression-free survival in patients with PD-L1–positive metastatic TNBC compared to chemotherapy alone. Median progression-free survival increased from 5.0 months to 7.5 months, representing a 38% reduction in disease progression risk (Schmid et al., New England Journal of Medicine, 2018).

Later, pembrolizumab (Keytruda) achieved FDA approval following the KEYNOTE-355 trial, which combined pembrolizumab with chemotherapy in metastatic TNBC. Among patients with PD-L1 expression (CPS ≥10), pembrolizumab improved median overall survival from 16.1 to 23.0 months, marking a 35% increase in survival (Cortes et al., Lancet, 2022). These findings have made pembrolizumab the cornerstone of immunotherapy in PD-L1–positive metastatic TNBC, greatly influencing the immunotherapy success rate for breast cancer.

Immunotherapy in Early-Stage Breast Cancer

Immunotherapy has shown even greater promise in early-stage disease, where it is used alongside chemotherapy to improve surgical and long-term outcomes. The KEYNOTE-522 trial demonstrated that pembrolizumab combined with chemotherapy before and after surgery improved both pathologic complete response (pCR) and event-free survival in high-risk early TNBC. Patients who received pembrolizumab achieved pCR in 64.8% of cases, compared to 51.2% with chemotherapy alone, while three-year event-free survival improved from 76.8% to 84.5% (Schmid et al., NEJM, 2022). This established pembrolizumab as part of the standard regimen for early-stage TNBC and significantly improved the immunotherapy success rate for breast cancer in this setting.

Subtype-Specific Success Rates

The immunotherapy success rate for breast cancer varies substantially across molecular subtypes. Triple-negative breast cancer remains the leading beneficiary, while other forms show more limited results.

In triple-negative breast cancer, immunotherapy combined with chemotherapy achieves objective response rates between 35% and 40% in metastatic PD-L1–positive disease and pathologic complete response rates above 60% in early-stage tumors. For HER2-positive breast cancer, research combining checkpoint inhibitors with trastuzumab or other HER2-targeted therapies has yielded response rates of 10–15% (Niikura et al., Cancer Science, 2021). In contrast, hormone receptor–positive breast cancer tends to be less immunogenic, and response rates are typically below 10%, though ongoing trials with checkpoint inhibitors and CDK4/6 inhibitors aim to improve outcomes (Emens et al., JCO, 2023).

Read About Breast Cancer Cure Rate on OncoDaily

Combination Strategies to Improve Success

To enhance the immunotherapy success rate for breast cancer, oncologists are exploring combination strategies that target multiple biological pathways simultaneously. Combining immunotherapy with chemotherapy has been the most successful, as chemotherapy can increase tumor antigen release and improve immune system recognition. Other promising combinations include immunotherapy with PARP inhibitors for BRCA-mutated tumors, radiotherapy to induce immunogenic cell death, and HER2-targeted agents to increase immune activation. Each approach aims to make resistant breast cancers more responsive to immunotherapy, thereby improving overall success rates.

Overall Success Rate and Outcomes

Current evidence shows that the immunotherapy success rate for breast cancer depends strongly on disease stage, tumor biology, and biomarker expression. Across all breast cancer subtypes, the average response rate to immunotherapy ranges from 20% to 30%. In PD-L1–positive TNBC, response rates reach up to 40% in metastatic disease and over 60% in early-stage cases when pembrolizumab is combined with chemotherapy. Meanwhile, patients without PD-L1 expression or with hormone receptor–positive disease generally experience limited benefits, underscoring the importance of biomarker-driven therapy.

Factors Influencing Immunotherapy Response

Several key factors influence the immunotherapy success rate for breast cancer. PD-L1 expression is the most reliable predictor of response, with higher expression correlating with better outcomes. Tumor-infiltrating lymphocytes also enhance immunogenicity, improving the effectiveness of checkpoint blockade. In addition, high tumor mutational burden (TMB) and BRCA mutations increase neoantigen formation, enhancing immune detection. These biomarkers are now routinely assessed to determine eligibility for immunotherapy.

Safety and Tolerability

Although immunotherapy has clear benefits, it can cause immune-related side effects, including thyroid inflammation, pneumonitis, hepatitis, and skin reactions. These events occur in about 15–20% of patients and are usually manageable with corticosteroids. Compared to traditional chemotherapy, immunotherapy tends to offer a more favorable safety profile, especially in long-term use.

Read About AI in Breast Cancer Detection on OncoDaily

Future Perspectives

The future of immunotherapy in breast cancer looks promising. Researchers are developing new immune checkpoint inhibitors targeting LAG-3, TIGIT, and TIM-3, as well as personalized cancer vaccines and CAR T-cell therapies directed at breast-specific antigens like MUC1 and HER2. Combining these approaches with genetic and immune profiling will likely increase the immunotherapy success rate for breast cancer even further, expanding its use beyond TNBC to other subtypes.

Conclusion

The immunotherapy success rate for breast cancer varies widely depending on tumor characteristics. The greatest benefits are seen in PD-L1–positive triple-negative breast cancer, where pembrolizumab and atezolizumab have shown remarkable results, with response rates of 35–65% depending on disease stage. In early-stage TNBC, immunotherapy combined with chemotherapy has become a standard treatment, significantly improving survival and cure potential. Although results remain modest in HER2-positive and hormone receptor–positive cancers, ongoing research and combination strategies are rapidly expanding immunotherapy’s impact. With continued scientific progress, the immunotherapy success rate for breast cancer is expected to rise, offering new hope to patients across the spectrum of disease.

You Can Watch More on OncoDaily Youtube TV

Written by Armen Gevorgyan, MD

Friday’s crypto sell-off was a fast, leverage-driven cascade that crushed altcoins while bitcoin held up comparatively better — and the next phase hinges on a handful of signals, according to Wiston Capital Founder Charlie Erith.

In a Sunday post titled “Crypto Crumble,” Erith said the market excluding bitcoin, ether and stablecoins fell about 33% in roughly 25 minutes on Oct. 10 before bouncing to a loss of around 10.6%. He added that about $560 billion, or 13.1%, has been erased from total crypto market value since Oct. 6 and cited $18.7 billion in liquidations during the episode.

He linked the immediate trigger to President Donald Trump’s Truth Social threat of an additional 100% tariff on Chinese imports, but argued the slide was already in motion — equities were still climbing while crypto “felt distinctly frail,” a divergence he took as advance warning.

Bitcoin, he said, “behaved largely as expected.” It fell, but less than the long tail, leaving bitcoin near a long-running uptrend from late 2022 and boosting its market share as non-bitcoin tokens absorbed “immense technical damage.” Erith said his fund emerged “largely unscathed” because positioning had already been defensively tilted.

What Erith is watching next

Erith said he is tracking bitcoin’s 365-day exponential moving average as a line that separates bullish from corrective regimes. He added that a pullback toward the $100,000 area and a touch of that average would not, by itself, overturn his longer-term view provided the level holds — but a sustained break would raise the risk of a deeper reset.

He also pointed to market breadth via bitcoin’s share of total crypto value. According to Erith, the sell-off accelerated a rotation toward higher-liquidity assets, lifting bitcoin dominance. He said a continued rise in that share alongside weak breadth would argue for caution in high-beta tokens until non-bitcoin charts rebuild.

Beyond bitcoin’s own levels, Erith highlighted Strategy’s equity as a proxy for leverage and sentiment in the ecosystem. He noted that roughly four years ago a decisive move below its 365-day average preceded a major bitcoin drawdown. In his view, holding above that trend line would support the resilience narrative; a break below could foreshadow renewed selling pressure.

Volatility is the other gauge. Erith said the VIX — the equity “fear index” — has started to climb and that historically better entries arrive when volatility spikes rather than during the early rise. That framing implies patience on adding risk while equity-volatility stress plays out.

On positioning, Erith said he remains invested but is avoiding leverage and is carrying cash “waiting for the dust to settle.” He said moves of this sort have, in his experience, sometimes preceded broader downturns, which is why he prefers to see the above signals stabilize before increasing exposure.

Erith said the sell-off inflicted heavy damage on altcoins, while bitcoin’s month-to-date decline is modest and comparable to large-cap tech, which he views as evidence of growing resilience.